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Abstract
Introduction: Matrix metalloproteinases (MMPs) are involved in aortic pathophysiology. Preliminary studies have
detected increased plasma levels of MMP8 and MMP9 in patients with acute aortic dissection (AAD). However, the
performance of plasma MMP8 and MMP9 for the diagnosis of AAD in the emergency department is at present
unknown.
Methods: The levels of MMP8 and MMP9 were measured by ELISA on plasma samples obtained from 126
consecutive patients evaluated in the emergency department for suspected AAD. All patients were subjected to
urgent computed tomography (CT) scan for final diagnosis.
Results: In the study cohort (N = 126), AAD was diagnosed in 52 patients and ruled out in 74 patients. Median
plasma MMP8 levels were 36.4 (interquartile range 24.8 to 69.3) ng/ml in patients with AAD and 13.2 (8.1 to 31.8)
ng/ml in patients receiving an alternative final diagnosis (P <0.0001). Median plasma MMP9 levels were 169.2 (93.0
to 261.8) ng/ml in patients with AAD and 80.5 (41.8 to 140.6) ng/ml in patients receiving an alternative final
diagnosis (P = 0.001). The area under the curve (AUC) on receiver-operating characteristic (ROC) analysis of MMP8
and MMP9 for the diagnosis of AAD was respectively 0.75 and 0.70, as compared to 0.87 of D-dimer. At the cutoff
of 3.6 ng/ml, plasma MMP8 had a sensitivity of 100.0% (95% CI, 93.2% to 100.0%) and a specificity of 9.5% (95% CI,
3.9% to 18.5%) and ruled out AAD in 5.6% of patients. Combination of plasma MMP8 with D-dimer increased the
AUC on ROC analysis to 0.89. Presence of MMP8 <11.0 ng/ml and D-dimer <1.0 or <2.0 µg/ml provided a negative
predictive value of 100% and ruled out AAD in 13.6% and 21.4% of patients respectively.
Conclusions: Low levels of plasma MMP8 can rule out AAD in a minority of patients. Combination of plasma
MMP8 and D-dimer at individually suboptimal cutoffs could safely rule out AAD in a substantial proportion of
patients evaluated in the emergency department.
Introduction
The prompt identification of acute aortic dissection
(AAD) in the emergency department (ED) is paramount
to reduce morbidity and mortality in affected patients, as
diagnostic delays lead to inappropriate clinical manage-
ment and defer life-saving treatments such as cardiothor-
acic surgery and/or endovascular repair [1,2]. However,
the diagnosis of AAD in the ED is highly challenging,
because AAD is rare (2-4 cases per 100,000 individuals
per year) and clinically heterogeneous at presentation
[3-5]. Currently, the diagnostic approach to suspected
AAD relies on imaging techniques such as computed
tomography (CT) scan and transesophageal echocardio-
graphy, which nonetheless require thorough pretest clini-
cal selection and may not be immediately available in all
EDs [2]. Therefore, identification of blood markers sup-
porting or refusing the diagnosis of AAD would provide
a major breakthrough. D-dimer, a well-established mar-
ker of vascular thrombosis, has shown high sensitivity but
low specificity for the diagnosis of AAD [6,7]. Ideal
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diagnostic markers of AAD would be components of the
aortic wall released into the bloodstream upon acute aor-
tic damage, similar to circulating troponin for acute myo-
cardial damage. On these grounds, different aortic
proteins have been examined, such as smooth muscle
myosin heavy chain, soluble elastin fragments and calpo-
nin [8-10]. However, none of them has been introduced
into clinical practice so far.
Matrix metalloproteinases (MMPs) constitute a large
family of calcium and zinc-dependent endopeptidases
that degrade the extracellular matrix [11]. MMPs are
key molecular mediators of aortic disease and contribute
to the landmark feature of extracellular matrix fragmen-
tation underlying AAD [12]. In particular, several lines
of evidence have shown that MMP9 (collagenase type
IV or gelatinase B) is activated in human aortic aneur-
ysms [13-16]. Instead, less is known about MMP8 (neu-
trophil collagenase I) in aortic disease.
Several studies have demonstrated an association
between aortic pathology and the circulating levels of
MMPs [17]. The plasma levels of MMP8 and MMP9
have also been shown to increase in AAD compared to
healthy controls and to selected patients with acute cor-
onary syndromes [18-21]. However, the utility of circulat-
ing MMP8 or MMP9 for the diagnosis of AAD in the ED
depends on their actual plasma levels in the far broader
spectrum of patients with clinically suspected AAD.
To evaluate the diagnostic performance of plasma
MMP8 and MMP9, their levels were evaluated in a pro-
spective cohort of patients managed in the ED for sus-
pected AAD. The diagnostic performance of MMP8 and
MMP9 was also compared to that of D-dimer, the only
routinely available circulating marker relevant to AAD.
Materials and methods
Study population
The present study was approved by the local Ethics Com-
mittee (Comitato Etico Interaziendale A.O.U. San Gio-
vanni Battista di Torino e A.O. C.T.O. Maria Adelaide di
Torino) and was performed in accordance with the
Declaration of Helsinki (1964). All patients included in the
study provided their informed consent (i) to enrolment
and (ii) to publication of scientific results. The plasma
levels of MMP8 and MMP9 were assayed in consecutive
patients evaluated for suspected AAD in the ED of the
Molinette Hospital of Turin, Italy, for a total of 26 months
starting from June 2010. Blood samples for MMP dosage
were obtained in the ED at the time of routine clinical eva-
luation. All patients included in the study were evaluated
within 24 hours after symptom onset.
Patients were eligible to the study if all the following
criteria were met: (i) clinical presentation suggestive of
AAD (chest pain, abdominal pain, back pain, syncope or
symptoms of perfusion deficit), as indicated by the 2010
guidelines of the American Heart Association [22];
(ii) order of an urgent chest and abdomen CT with con-
trast by the caring physician to expressly rule out AAD;
(iii) informed consent of the participant. To confirm
appropriateness of enrolment, cases were subsequently
re-evaluated by independent reviewers based on clinical
charts and written requests for urgent CT originally
filled out by the caring physician. Reviewers were
blinded to the results of CT scan, blood tests and final
diagnosis. Final alternative diagnoses were based on
patient dismissal for hospitalized patients and on ED
dismissal for outpatients.
Matrix metalloproteinases
Blood samples were obtained from all patients in EDTA-
containing tubes during their routine medical evaluation
in the ED, when the other blood samples for routine diag-
nostic tests were drawn, and immediately sent to the
laboratory. Plasma was obtained by centrifugation at 4,000
rpm for 5 minutes and stored at -80ºC until further pro-
cessing. Plasma levels of MMP8 and MMP9 were mea-
sured by ELISA (Amersham™; GE Healthcare, Chalfont
St Giles, UK). The assay is based on a two-site ELISA
sandwich format using two antibodies (for capture and
detection) directed against different epitopes of MMPs.
The precision analysis for measurement of MMP8 and
MMP9 yielded coefficients of variation (CV%) of 2.3% and
5.5%, respectively for within assay tests, and of 2.5% and
9.8% respectively for between-assay tests.
Biochemical analyses
Creatinine, troponin T, lactate dehydrogenase (LDH) and
C-reactive protein (CRP) were measured with the auto-
mated Cobas C8000 chemistry analyzers (Roche Diagnos-
tics GmbH, Mannheim, Germany). D-dimer levels were
measured with the automated STA LIATEST™ D-DI,
based on latex agglutination (Diagnostica Stago for Roche
Diagnostics GmbH, Mannheim, Germany).
Statistical analysis
Statistical analysis was performed with GraphPad Prism
Software version 5.0 (GraphPad Software, San Diego,
CA, USA). Data are presented as median and interquar-
tile range (IQR), as the distribution of all biochemical
variables (including MMP8 and MMP9) in the study
population was not normal. Statistical tests used in the
study were nonparametric Mann-Whitney U test, non-
parametric Dunn’s test for multiple comparisons, Fish-
er’s exact test and nonparametric Spearman correlation.
Statistical comparison of different ROC curves was per-
formed as previously described [23]. P values lower than
0.05 were considered as statistically significant.
Giachino et al. Critical Care 2013, 17:R33
http://ccforum.com/content/17/1/R33
Page 2 of 8
Results
Patient cohort
In the study period, 186 patients managed in the ED for
suspected AAD were eligible for the study. The number
of enrolled patients was 126 (67.7%). In these individuals,
chief complaints were chest pain (60%), abdominal pain
(17%), back pain (30%), syncope (5%) and other symp-
toms (17 %), in line with previous reports [3]. In this
cohort, AAD was finally diagnosed in 52 patients (41.3%),
including 32 cases of Stanford type A and 20 cases of
Stanford type B AAD. AAD was initially suspected but
finally ruled out by CT scan in 74 patients (58.7%). In
these individuals, alternative final diagnoses included aor-
tic aneurysm without signs of dissection (n = 16), inflam-
matory disease (n = 6), acute coronary syndrome (n = 5),
other diagnoses (n = 8) and uncertain diagnoses (n = 39).
The demographic and clinical characteristics of enrolled
individuals are presented in Table 1.
Plasma levels of MMP8 and MMP9
The routine biochemical profile of patients with AAD
and of patients receiving an alternative final diagnosis is
presented in Table 2. Median D-dimer levels were 7.16
µg/ml (2.81 to 18.70) in patients with AAD and 1.34 µg/
ml (0.35 to 2.31) in patients receiving an alternative final
diagnosis (P <0.0001), in line with previous reports [6,7].
Also LDH was significantly higher in AAD compared to
controls (P = 0.02). No significant differences were
observed in the other biochemical variables.
Median MMP8 levels were 36.4 ng/ml (24.8 to 69.3) in
patients with AAD and 13.2 ng/ml (8.1 to 31.8) in
patients receiving a final alternative diagnosis (P <0.0001,
Figure 1a). MMP8 levels were 39.9 ng/ml (26.8 to 72.3)
in patients with Stanford type A AAD and 34.2 ng/ml
(14.7 to 64.2) in patients with Stanford type B AAD (P =
0.32). MMP8 levels of control patients according to alter-
native final diagnoses are reported in Table 3. In patients
receiving an alternative final diagnosis, the highest levels
of plasma MMP8 were observed in individuals affected
by an inflammatory disease. Of note, plasma MMP8 was
not increased in patients with uncomplicated aortic
aneurysm, suggesting that aortic dilation per se is not suf-
ficient to significantly increase the circulating levels of
MMP8 in this patient population.
Median MMP9 levels were 169.2 ng/ml (93.0 to 261.8)
in patients with AAD and 80.5 ng/ml (41.8 to 140.6) in
patients receiving a final alternative diagnosis (P = 0.0001,
Figure 1b). Median MMP9 levels were 204.9 ng/ml (104.1
to 296.3) in patients with Stanford type A dissection and
126.6 ng/ml (70.91 to 197.0) in patients with type B dis-
section (P = 0.13). Plasma MMP9 levels of control
patients according to alternative diagnoses are reported in
Table 3. In patients receiving an alternative final diagno-
sis, the highest levels of plasma MMP9 were also observed
in individuals affected by an inflammatory disease. Of
note, plasma MMP9 was not increased in patients with
uncomplicated aortic aneurysm, suggesting that aortic
dilation per se is not sufficient to significantly increase cir-
culating levels of MMP9 in this patient population.
Correlation of plasma MMPs with CRP and D-dimer
Plasma levels of MMP8 and MMP9 were highly corre-
lated (Figure 1c, Spearman r = 0.63, P <0.0001). Neither
plasma MMP8 nor plasma MMP9 correlated with crea-
tinine. Plasma MMP8 presented a slight albeit signifi-
cant correlation with CRP (Spearman r = 0.22,
P = 0.022) and a stronger correlation with D-dimer
(Spearman r = 0.32, P <0.001). Also MMP9 correlated
with both CRP (Spearman r = 0.29, P = 0.003) and D-
dimer (Spearman r = 0.27, P = 0.005).
Table 1 Demographic and nosological characteristics of enrolled patients.
AAD Alternative diagnosis P
N 52 (41.3%) 74 (58.7%)
Stanford Alternative diagnoses:
classification: - Uncomplicated aortic aneurysm (16)
- type A AAD (32) - Inflammatory disease (6)
- type B AAD (20) - Pneumonia (3), pericarditis (1), pancreatitis (1), urinary tract infection (1)
- Acute coronary syndrome (5)
- Other diagnoses (8)
- Uncertain diagnoses (39)
Gender (M/F) 40/12 49/25 0.24
Age (years) 66.3 ± 1.9 64.0 ± 1.7 0.39
Hypertension 31 (59.6%) 44 (59.5%) 1.00
Diabetes 1 (1.9 %) 11 (14.9%) 0.02
Age is reported as mean ± standard deviation. P values are calculated with Fisher’s exact test. AAD, acute aortic dissection.
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Receiver-operating characteristics curve analysis of
plasma MMP8 and MMP9
The receiver-operating characteristics (ROC) curves of
MMP8, MMP9 and D-dimer for the diagnosis of AAD
are presented in Figure 2. For D-dimer, the AUC on
ROC analysis for patients with AAD was 0.87 (95% CI,
0.80 to 0.94) versus all controls, in line with previous
reports [7]. Using a cutoff of 0.50 µg/ml, D-dimer
showed a sensitivity of 97.6% (95% CI, 87.4% to 99.9%)
and a specificity of 32.8% (95% CI, 21.3% to 46.0%). In
the study cohort, D-dimer levels were <0.50 µg/ml in 1/
42 (2.4%) patients with AAD (false negatives) and in 20/
61 (32.8%) patients without AAD (true negatives).
For MMP8, the AUC on ROC analysis for patients
with AAD was 0.75 (95% CI, 0.66 to 0.84) versus all
controls, 0.75 (95% CI, 0.59 to 0.91) versus aortic aneur-
ysm without dissection, 0.67 (95% CI, 0.42 to 0.91) ver-
sus inflammatory disease, 0.82 (95% CI, 0.69 to 0.95)
versus acute coronary syndrome, 0.66 (95% CI, 0.44 to
0.88) versus other diagnoses and 0.82 (95% CI, 0.73 to
0.91) versus uncertain diagnoses. Using a cutoff of 3.6
ng/ml, plasma MMP8 had a sensitivity of 100.0% (95%
CI, 93.2% to 100.0%) and a specificity of 9.5% (95% CI,
3.9% to 18.5%). In the study cohort, plasma MMP8
levels were <3.6 ng/ml in 0/52 patients (0%) with AAD
(false negatives) and in 7/74 (9.5%) patients without
AAD (true negatives).
For MMP9, the AUC on ROC analysis for patients with
AAD was 0.70 (95% CI, 0.61 to 0.80) versus all controls,
0.77 (95% CI, 0.63 to 0.91) versus aortic aneurysm with-
out signs of dissection, 0.69 (95% CI, 0.45 to 0.93) versus
inflammatory disease, 0.73 (95% CI, 0.56 to 0.89) versus
acute coronary syndrome, 0.54 (95% CI, 0.31 to 0.78) ver-
sus other diagnoses and 0.76 (95% CI, 0.66 to 0.86) versus
uncertain diagnoses. Using a cutoff of 20.0 ng/ml, plasma
MMP9 had a sensitivity of 96.2% (95% CI, 86.8% to
99.5%) and a specificity of 16.2% (95% CI, 8.7% to 26.6%).
In the study cohort, plasma MMP9 levels were <20.0 ng/
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Figure 1 Plasma levels (ng/ml) of MMP8 (a) and MMP9 (b) in
patients with acute aortic dissection (AAD) and in patients
receiving a final alternative diagnosis. Y-axis: log2 scale. ***P
<0.0001, ¶¶¶P = 0.0001 by nonparametric Mann-Whitney U test.
(c) Correlation of plasma MMP8 and plasma MMP9 in enrolled
patients. MMP, matrix metalloproteinase.
Table 2 Biochemical profile of enrolled patients.
AAD Alternative diagnosis P
Creatinine
(mg/dl)
1.02 (0.86-1.32) [N =
48]
0.99 (0.77-1.31) [N =
71]
0.21
LDH (IU/l) 415 (370-651) [N = 23] 371 (329-424) [N = 42] 0.02
Troponin-T
(μg/dl)
0.010 (0.006-0.029) [N
= 45]
0.010 (0.008-0.013) [N
= 67]
0.69
CRP (mg/dl) 4.4 (1.6-34.3) [N = 40] 5.2 (0.9-17.5) [N = 63] 0.36
D-dimer (µg/
ml)
7.16 (2.81-18.70) [N =
42]
1.34 (0.35-2.31) [N =
61]
0.0001
Values are presented as median and interquartile range (IQR). N represents
the sample number for each biochemical value. P values are calculated with
nonparametric Mann-Whitney U test. AAD, acute aortic dissection; CRP, C-
reactive protein; LDH, lactate dehydrogenase.
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ml in 2/52 (3.8%) patients with AAD (false negatives) and
in 12/74 (16.2%) patients without AAD (true negatives).
Combination of plasma MMP8 with D-dimer
Next, we tested the hypothesis that a combined use of
plasma MMP8 and D-dimer may: (i) increase the diagnos-
tic accuracy of MMP8 alone, and (ii) safely rule out AAD
in a clinically significant proportion of patients. Indeed,
calculation of the AUC on ROC analysis demonstrated
better performance of a combination of MMP8 and
D-dimer than plasma MMP8 alone (P <0.05, Figure 2 and
Table 4). Table 5 reports the negative predictive values
(NPV) obtained by combination of three different diagnos-
tic cutoffs for MMP8 and D-dimer. Of note, the NPV of
plasma MMP8 at the cutoff of 11.0 ng/ml increased from
84.2% when used alone to 100% when used in association
with any proposed D-dimer cutoff (0.5, 1.0 or 2.0 µg/ml).
Furthermore, combination of MMP8 <11.0 ng/ml with
any D-dimer cutoff identified up to 22 true negatives in
the study cohort and was not associated with false nega-
tives, as compared to 6 false negatives with MMP8 <11.0
ng/ml alone. These findings indicate that a combined use
of plasma MMP8 and D-dimer represents a promising
strategy to safely rule out AAD in a significant proportion
of patients in the ED.
Discussion
The present study is, to the best of our knowledge, the
first to evaluate the levels of plasma MMP8 and MMP9
in a prospective cohort of patients managed in the ED
for suspected AAD, and thus to directly estimate the
actual diagnostic value of these markers. Previous case-
control studies have reported increased plasma levels of
MMP8 and MMP9 in AAD [18,20]. These studies had a
retrospective design and focused on selected groups as
controls, such as normal individuals and patients with
acute coronary syndrome. However, the differential
diagnoses of AAD are multiple and highly heteroge-
neous [24]. In the present ED-based study cohort, for
instance, 6.8% of patients without AAD were finally
diagnosed with acute coronary syndrome, while 8.1%
received a diagnosis of inflammatory disease such as
pancreatitis or pneumonia, thus reflecting the wide
spectrum of differential diagnosis.
In the present study, median plasma levels of MMP8
and MMP9 were respectively 2.8-fold and 2.1-fold
higher in AAD than in patients receiving alternative
Table 3 Plasma levels of MMP8 and MMP9 in acute aortic
dissection versus alternative diagnoses.
N MMP8 (ng/ml) MMP9 (ng/ml)
Acute aortic dissection 52 36.4 (24.8-69.3)a,
f
169.2 (93.0-261.8)e,
g
Uncomplicated aortic
aneurysm
16 10.7 (4.6-33.9)a 54.4 (20.9-96.6)e,b
Inflammatory disease 6 60.8 (31.6-
105.5)d
294.0 (125.8-407.6)
b,c
Acute coronary syndrome 5 12.90 (8.1-29.0) 92.4 (58.1-152.5)
Other diagnoses 8 17.6 (12.9-69.3) 137.1 (63.3-340.5)
Uncertain diagnoses 39 10.5 (7.3-22.9)d,f 78.8 (35.4-127.6)c,g
Values are presented as median and interquartile range (IQR). a,b,cP <0.05; d,eP
<0.01; f,gP <0.001 by nonparametric Dunn’s multiple comparison test. MMP,
matrix metalloproteinase.
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Figure 2 Receiver-operating characteristics (ROC) curve of plasma MMP8, plasma MMP9, D-dimer and combination of MMP8 and D-
dimer (log2MMP8*D-dimer) for patients with acute aortic dissection versus subjects receiving an alternative final diagnosis. MMP,
matrix metalloproteinase.
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diagnoses. The plasma levels of MMP8 and MMP9 were
highly correlated, indicating that leakage of these pro-
teins into the bloodstream relates to the same biological
processes. As plasma MMP8 and MMP9 were similar in
patients with uncomplicated aortic aneurysm and in
patients with other unspecific diagnoses having a regular
aortic size, aortic dilation per se does not appear as a
major determinant of plasma MMP8 and MMP9 in the
selected population of patients.
Based on AUC analysis, the overall performance of
plasma MMP8 and MMP9 for the diagnosis of AAD is
limited and inferior to that of D-dimer, the only marker
of AAD currently available in clinical practice [6,7]. This
is largely due a substantial variability of plasma MMP8
and MMP9 in patients without AAD, which leads to neg-
ligible specificity and positive predictive value of these
markers. In particular, high circulating levels of MMP8
and MMP9 were found in patients affected by inflamma-
tory conditions, such as pancreatitis and pneumonia.
This is in line with the notion that MMP8 and MMP9
are expressed by neutrophils and with previous reports
that plasma MMP9 is increased in acute pancreatitis
[19,25]. Indeed, both plasma MMP8 and MMP9 slightly
but significantly correlated with CRP levels in the present
study population.
The present results clearly demonstrate that plasma
MMP8 and MMP9 are unsuitable per se to diagnose
AAD in patients presenting to the ED with suggestive
symptoms. Instead, our data indicate that low plasma
levels of MMP8 could be used to rule out AAD. For
instance, rule out of AAD in the presence of MMP8
<3.6 ng/ml could avoid 7/126 urgent CT scans in the
study cohort, corresponding to a 5.6% reduction in the
number of urgent CT scans performed in the ED for
suspected AAD. The CT scans in question were per-
formed in four patients with uncomplicated aortic
aneurysm and in three patients with other unspecific
diagnoses, and did not provide any additional clinical
benefit. Several studies have shown that also D-dimer
has favorable rule-out properties for AAD. In our study
cohort, rule out of AAD in the presence of D-dimer
<0.50 µg/ml could avoid 21/103 urgent CT scans, corre-
sponding to a 20.4% reduction in the number of urgent
CT scans performed in the ED for suspected AAD.
However, the latter approach would lead to one missed
diagnosis of Stanford type B AAD, with presumably dra-
matic clinical consequences. These data indicate that,
although D-dimer shows a better ROC curve than
plasma MMP8 for the diagnosis of AAD, MMP8 may
provide better sensitivity and lower rates of false nega-
tives if a sufficiently low cutoff is applied.
A major finding of the present study is that combina-
tion of low plasma MMP8 and low D-dimer has the
potential to safely rule out AAD. In our cohort, combina-
tion of plasma MMP8 <11.0 ng/ml and D-dimer <1.0 or
<2.0 µg/ml (that is individually suboptimal cutoffs for
both markers) provided a NPV of 100%. Rule out of AAD
with MMP8 <11.0 ng/ml and D-dimer <1.0 or <2.0 µg/ml
could avoid respectively 14/103 or 22/103 urgent CT
scans, corresponding to a 13.6% or 21.4% reduction in
the number of urgent CT scans for suspected AAD, with-
out any missed diagnosis of AAD. In order to limit costs,
plasma MMP8 levels might be measured only in patients
Table 4 ROC analysis for plasma MMP8, D-dimer and their combination.
AUC
(95% CI)
Cutoff Sensitivity %
(95% CI)
Specificity %
(95% CI)
MMP8 0.75a,b,c
(0.66-0.84)
>3.6
ng/ml
100%
(93.2%-100.0%)
9.5%
(3.9%-18.5%)
DD 0.87a
(0.80-0.94)
>0.50
µg/ml
97.6%
(87.4%-99.9%)
32.8%
(21.3%-46.0%)
DD*MMP8 0.87b
(0.80-0.94)
>2.44 100%
(91.6%-100.0%)
16.4%
(8.2%- 28.1%)
DD*log2(MMP8) 0.89
c
(0.82-0.95)
>0.77 100%
(91.6%-100.0%)
13.1%
(5.8%- 24.2%)
aP = 0.048, bP = 0.034, cP = 0.018. AUC, area under the curve; DD, D-dimer; MMP, matrix metalloproteinase; ROC, receiver-operating characteristics.
Table 5 Negative predictive value of plasma MMP8 in
combination with D-dimer.
NPV D-dimer (µg/ml)
AND Any value <0.5 <1.0 <2.0
<3.6 100%
TN 7, FN 0
100%
TN 1, FN
0
100%
TN 1, FN
0
100%
TN 3, FN
0
MMP8 (ng/
ml)
<11.0 84.2%
TN 32, FN
6
100%
TN 12, FN
0
100%
TN 14, FN
0
100%
TN 22, FN
0
<30.0 73.2%
TN 52, FN
19
94.1%
TN 16, FN
1
95.5%
TN 21, FN
1
93.9%
TN 31, FN
2
Any
value
95.2%
TN 20, FN
1
96.6%
TN 28, FN
1
93.3%
TN 42, FN
3
Three representative cutoffs are presented for each biomarker. NPV, negative
predictive value (%); TN, true negatives; FN, false negatives; MMP, matrix
metalloproteinase.
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with elevated D-dimer levels. In this scenario, turnaround
time could be limited by applying rapid point-of-care
testing of D-dimer in the ED [26].
Taken together, results from the present study indicate
that the plasma levels of MMP8 may assist emergency
physicians in evaluating the necessity to perform urgent
secondary imaging in patients with clinical presentations
suggestive of AAD. Extrapolating data from the study
cohort, plasma MMP8 alone has the potential to avoid
one urgent CT scan every twenty patients with a clinical
suspicion of AAD, while combination of MMP8 and D-
dimer could avoid as much as one urgent CT scan every
five patients. In the context of a continuous increase in
the rate of CT use in EDs (for example 5- and 10-fold
increases in a decade for the categories of chest and
abdominal pain), the benefits of such an approach will
clearly depend on the respective site-specific costs, avail-
ability and turnaround times of biochemical assays and
urgent secondary imaging [27].
While the struggle for a specific aortic biomarker con-
tinues, validation of robust rule-out approaches may
pave our way toward a safer and more cost-effective
management of suspected AAD in EDs while avoiding
an exponential increase in urgent CTs.
Limitations
A number of limitations apply to the present findings.
First, data on diagnostic accuracy clearly depend on the
enrolled population of patients. We applied for enrolment
the diagnostic algorithm suggested by the American
Heart Association [22]. However, the diagnostic perfor-
mance of this algorithm is largely unknown, especially in
the context of EDs [28]. Furthermore, even compliance
with these guidelines does not eliminate a substantial
amount of subjectivity in the clinical suspicion of AAD
and thus in the decision of the caring physician to per-
form an urgent CT. Second, we acknowledge that sample
size constitutes a significant limitation of the present
study. In particular, we provide proof-of-concept that
combination of D-dimer with plasma MMP8 at individu-
ally suboptimal cutoffs could provide a better rule-out
profile than D-dimer alone. However, D-dimer was mea-
sured in only 103/126 patients enrolled in the present
study (81.7%). Hence, conclusive demonstration of statis-
tical superiority requires a substantial increase in patient
number. Given the low incidence of AAD, multicenter
studies are presumably needed for the purpose.
Conclusions
In a prospectively enrolled cohort of patients evaluated in
the ED, plasma MMP8 and MMP9 showed negligible spe-
cificity for the diagnosis of AAD. Plasma MMP8 demon-
strated better diagnostic performance than plasma MMP9,
but both MMP8 and MMP9 were inferior to D-dimer on
ROC analysis. However, use of a low cutoff for plasma
MMP8 (3.6 ng/ml) provided high sensitivity to rule out
AAD and allowed a potential 5% reduction in urgent sec-
ondary imaging. Combined use of plasma MMP8 and
D-dimer at individually suboptimal cutoffs provided opti-
mal negative predictive value and allowed a potential 20%
reduction in urgent secondary imaging.
Key messages
• While plasma MMP8 and MMP9 lack specificity for
AAD, low plasma MMP8 levels have satisfactory rule-
out properties for AAD in the ED.
• Combination of D-dimer and plasma MMP8 could
be used to avoid a significant amount of urgent second-
ary imaging in patients evaluated for suspected AAD in
the ED.
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